Published by mark itwired
Posted on September 2, 2021
7 min readLast updated: February 13, 2026
Add as preferred source on Google
Global injectable benzodiazepine sales are set to reach USD 260 million in 2020, as covid-19 panic and uncertainty has set in, even among population with no previous history of mental illnesses, according to a new study by Future Market Insights (FMI). The market research firm estimates the market to grow at 2.7% CAGR through 2030.
Although covid-19 will create a short-term spike, in the long run, the market is likely to be driven by increasing demand for generic drugs. Growing acceptance of injectables as a route of administration is also likely to drive growth.
Low cost manufacturing and large patient pools in Asian countries expected to be a key growth driver in the forecast period
“Growing incidences of seizures and anxiety followed by demand for generics to boost the global injectable benzodiazepine market,” says an FMI Analyst.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724
The market players are emphasizing on expanding their manufacturing facilities with introduction of cost-effective and generic drugs and also venturing into strategic partnerships.
Future market insights offer a unique perspective and actionable insights on injectable benzodiazepine market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by time of action (short acting long acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) in seven key regions.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Per Capita Healthcare Expenditure Outlook
4.1.3. Overall Psychoactive Drugs Market
4.2. Forecast Factors – Relevance & Impact
4.2.1. Increasing Incidence of Anxiety, Seizures, Insomnia
4.2.2. Increasing Usage as Anaesthesia
4.2.3. Dose Per Case
4.2.4. Treatment Cost
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. Market Context
5.1. Product Adoption / Usage Analysis By Indication
5.2. Disease Epidemiology, By Region
5.3. Regulatory Scenario
5.4. Reimbursement Landscape
5.5. Key Promotional Strategies, By Manufacturers
5.6. COVID19 Crisis Analysis
5.6.1. Current COVID19 Statistics and Probable Future Impact
5.6.2. Current GDP Projection and Probable Impact
5.6.3. COVID19 and Impact Analysis
5.6.3.1. Revenue By Class
5.6.3.2. Revenue By Country
5.6.4. 2020 Market Scenario
5.6.5. Quarter by Quarter Forecast
5.6.6. Projected recovery Quarter
5.6.7. Recovery Scenario – Short term, Midterm and Long Term Impact
The post Injectable Benzodiazepine Market is Anticipated to Gain CAGR of 2.7% by 2030 first appeared on Market Research Blog.
Global injectable benzodiazepine sales are set to reach USD 260 million in 2020, as covid-19 panic and uncertainty has set in, even among population with no previous history of mental illnesses, according to a new study by Future Market Insights (FMI). The market research firm estimates the market to grow at 2.7% CAGR through 2030.
Although covid-19 will create a short-term spike, in the long run, the market is likely to be driven by increasing demand for generic drugs. Growing acceptance of injectables as a route of administration is also likely to drive growth.
Low cost manufacturing and large patient pools in Asian countries expected to be a key growth driver in the forecast period
“Growing incidences of seizures and anxiety followed by demand for generics to boost the global injectable benzodiazepine market,” says an FMI Analyst.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724
The market players are emphasizing on expanding their manufacturing facilities with introduction of cost-effective and generic drugs and also venturing into strategic partnerships.
Future market insights offer a unique perspective and actionable insights on injectable benzodiazepine market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by time of action (short acting long acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) in seven key regions.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Per Capita Healthcare Expenditure Outlook
4.1.3. Overall Psychoactive Drugs Market
4.2. Forecast Factors – Relevance & Impact
4.2.1. Increasing Incidence of Anxiety, Seizures, Insomnia
4.2.2. Increasing Usage as Anaesthesia
4.2.3. Dose Per Case
4.2.4. Treatment Cost
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. Market Context
5.1. Product Adoption / Usage Analysis By Indication
5.2. Disease Epidemiology, By Region
5.3. Regulatory Scenario
5.4. Reimbursement Landscape
5.5. Key Promotional Strategies, By Manufacturers
5.6. COVID19 Crisis Analysis
5.6.1. Current COVID19 Statistics and Probable Future Impact
5.6.2. Current GDP Projection and Probable Impact
5.6.3. COVID19 and Impact Analysis
5.6.3.1. Revenue By Class
5.6.3.2. Revenue By Country
5.6.4. 2020 Market Scenario
5.6.5. Quarter by Quarter Forecast
5.6.6. Projected recovery Quarter
5.6.7. Recovery Scenario – Short term, Midterm and Long Term Impact
The post Injectable Benzodiazepine Market is Anticipated to Gain CAGR of 2.7% by 2030 first appeared on Market Research Blog.
Benzodiazepines are a class of medications primarily used to treat anxiety, insomnia, and seizures. They work by enhancing the effects of a neurotransmitter called GABA in the brain.
Market analysis is the process of assessing the market for a product or service, including understanding the competitive landscape, customer preferences, and market trends.
CAGR stands for Compound Annual Growth Rate. It is the rate at which an investment grows annually over a specified period, assuming the profits are reinvested at the end of each period.
Generic drugs are medications that have the same active ingredients as brand-name drugs but are sold under their chemical name without the brand label, usually at a lower cost.
Market trends indicate the general direction in which a market is moving. Understanding these trends helps businesses make informed decisions regarding product development and marketing strategies.
Explore more articles in the Research Reports category
